Rectal Cancer Clinical Trial
— PMCRBDSPSOfficial title:
A Prospective, Randomization and Clinic Cohort Observational Study From Multi Institutions on Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
This research plans to collect rectal cancer patients after sphincter-preserving surgery from 14 institutions in China mainland, observe the incidence and risk factors about bowel dysfunction after operation.
Status | Not yet recruiting |
Enrollment | 460 |
Est. completion date | December 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age = 18 years 2. Adenocarcinoma confirmed by pathology 3. Distance from the lowest margin of tumor to the anal verge is = 12cm, confirmed by hard sigmoidoscope. 4. The tumor is estimated to be resectable and confirmed by multidisciplinary team (MDT). 5. The operation is estimated to be sphincter-preserving. 6. The Eastern Cooperative Oncology Group(ECOG) performance status score of patient is = 2. 7. The estimated life time is not less than one year. 8. The patient agree to sign the informed consent. Exclusion Criteria: 1. The patient refuse to follow research plan. 2. Emergency case 3. Pregnant and lactating female patient 4. The patient did not accept radical resection. 5. The patient did not accept first stage resection and anastomosis. 6. The patient has experienced anal-rectal surgery. 7. The patient has experienced left colon surgery. 8. The patient suffered long-existing bowel dysfunction before rectal cancer diagnosis. 9. The patient was diagnosed with cognitive or communicative obstacles. 10. The patient was diagnosed with serious repeated infection or other concomitance diseases. 11. The patient has participated other medical research which may affect his/her bowel function. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital | Beijing Cancer Hospital, Beijing Friendship Hospital, Changshu NO.1 People's Hospital, China-Japan Friendship Hospital, First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hebei Medical University Fourth Hospital, Peking University International Hospital, Qilu Hospital of Shandong university in Qingdao, The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, The First Affiliated Hospital of Anhui Medical University, the first affiliated hospital of Jiamusi university, Xiangya Hospital of Central South University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of bowel dysfunction after sphincter-preserving surgery | one year | Yes | |
Primary | Risk factors of bowel dysfunction after sphincter-preserving surgery | one year | Yes | |
Secondary | Incidence of each symptoms of bowel dysfunction | one year | Yes | |
Secondary | Prognosis of bowel dysfunction after sphincter-preserving surgery | one year | Yes | |
Secondary | Incidence of bowel dysfunction after sphincter-preserving surgery | comparing incidences between high and low anastomsis site | one year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |